ArticleScientific reports2026
Concurrent Toxoplasma gondii infection and neuroinflammation in traumatic brain injury patients in a referral hospital in Douala Cameroon.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Studies on murine models show that Toxoplasma gondii infection reduces cerebral microvascular perfusion and induces neuroinflammation by activating cerebral endothelial cells, which could affect traumatic brain injury (TBI) outcomes. Whether TBI inflammatory profile and outcomes differ in persons with concurrent latent infection with Toxoplasma gondii has not yet been elucidated in TBI patients, constituting the core of this study. Understanding the impact of chronic T. gondii infection on neuroinflammation after TBI may ensure better management and prognosis of TBI. This study aimed to investigate the inflammatory profile in TBI patients and investigate the influence of concurrent T. gondii infection on inflammatory markers and TBI outcomes. The level of inflammatory markers [interleukin (IL)-1β, IL-6, IL-10, interferon-gamma (INF-ɣ), Tumour necrosis factor-alpha (TNF-α)], and Toxoplasma gondii infection were detected in serum obtained < 24 h post-injury. Glasgow Outcome Scale-Extended (GOSE) was used to evaluate the 6-month outcome post-discharge. The Wilcoxon and Kruskal-Wallis's rank sum tests were used to compare concentrations of inflammatory markers to T. gondii infection and TBI outcome. T. gondii infection was detected in 33% (52/160) of TBI cases. There was a significant increase (p < 0.001) in the concentrations of all inflammatory markers (IM) in TBI patients compared with the healthy controls. Higher levels of IL-6, INF-ɣ, and TNF-α were associated with mortality. Findings from this study show an increase in IM levels for all the T. gondii-positive TBI cases, which were significant for IL-1β (P < 0.001) and TNF-α (P < 0.001). IL-1β and TNF-α, had significantly greater density values, above 30pg/mL and 90pg/mL, respectively, in TBI patients infected with T. gondii, compared to greater density values, below 30 pg/mL and 90 pg/mL, respectively, for TBI patients seronegative to T. gondii. Concurrent T. gondii infection in TBI significantly influenced the inflammation profile of patients. Further multicenter studies with larger sample sizes will provide more insights into T. gondii induced neuropathology and prognostication in TBI care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.